Archive for the ‘Featured’ Category
INTERVIEW: PyroGenesis $PYR.ca Discusses Completion of Ramp-Up Phase of 1st Plasma Atomization System, 3 NDAs being negotiated with multinational aircraft engine manufacturers
Esports Entertainment Group $GMBL Files Annual Report And Reviews Highlights
PyroGenesis $PYR.ca Announces Completion of Ramp-Up Phase of 1st Plasma Atomization System
Tartisan Resources Corp. $TTC.ca to Acquire Canadian Arrow Mines Limited $CRO.ca
- Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
- Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan
TORONTO, Oct. 20, 2017 – Canadian Arrow Mines Limited (TSX.V:CRO) – (“Canadian Arrow”) announces that a definitive arrangement agreement (the “Agreement”) has been signed with Tartisan Resources Corp. (CSE: TTC) – (“Tartisan”) whereby Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited (“Canadian Arrow”) by way of a court-approved plan of arrangement (the “Arrangement”) in accordance with the Business Corporations Act (Ontario) in exchange for common shares in the capital of Tartisan.
Pursuant to the terms of the Agreement, Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan. Additionally, Tartisan would issue up to 4,500,000 common shares of Tartisan to settle Canadian Arrow debt pursuant to debt conversion agreements with various Canadian Arrow creditors. Certain lock up provisions are included in the Debt Conversion Agreements. Tartisan has also agreed to pay the transaction related expenses of Canadian Arrow.
The proposed transaction provides Canadian Arrow shareholders with liquidity, sustaining capital and an opportunity to participate in the potential upside of Tartisan.
The board of directors of Canadian Arrow (the “Canadian Arrow Board”) has approved the Arrangement and the entering into of the Arrangement Agreement and has determined to recommend that shareholders of Canadian Arrow vote in favour of the Arrangement. Completion of the Arrangement is subject to customary closing conditions, including approval of the Ontario Superior Court of Justice (Commercial List), the approval of holders of not less than 66 2/3% of the holders of Canadian Arrow Shares voted at a special meeting of Canadian Arrow shareholders that will be called to approve the Arrangement (the “Special Meeting”) as well as majority of the minority approval as required under applicable Canadian securities laws. The Arrangement is also subject to the approval of the TSX Venture Exchange, the Canadian Securities Exchange and all applicable regulatory authorities, as well other conditions typical for a transaction of this nature.
The terms of the Arrangement will be summarized in an information circular of Canadian Arrow (the “Circular”) that is anticipated to be mailed to the shareholders of Canadian Arrow in connection with the Special Meeting which is expected to be held in early January 2018. Canadian Arrow has received from Harris Capital Corporation an opinion that the Arrangement consideration is fair, from a financial point of view, to the shareholders of Canadian Arrow, and retained Fogler Rubinoff LLP as its legal counsel. Robert M. Isles is acting as legal counsel to Tartisan. A copy of the Arrangement Agreement, the Circular and related documents will be filed with the Canadian regulatory authorities and will be available for review under Canadian Arrow’s SEDAR profile at www.sedar.com.
The Agreement contains customary non-solicitation provisions which are subject to Canadian Arrow’s right to consider and accept a superior proposal subject to a matching right in favour of Tartisan. In the event that the Arrangement is not completed as a result of a superior proposal or for other certain specified circumstances, Canadian Arrow will pay Tartisan a termination fee of $100,000.
The Arrangement constitutes a “business combination” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) for Canadian Arrow as Canadian Arrow is indebted to certain of its directors and such indebtedness will be settled through the issuance of common shares of Tartisan in connection with the closing of the Arrangement. The indebtedness of Dean MacEachern is approximately $9,000, the indebtedness of Kim Tyler is approximately $5,000 and the indebtedness of George Pirie is approximately $20,000. Although Canadian Arrow does not consider the amounts of such indebtedness to be material the fact that such indebtedness is being satisfied through the issuance of common shares of Tartisan in connection with the completion of the Arrangement means that the Arrangement is considered to be a Business Combination for the purposes of MI 61-101. Canadian Arrow is relying on the formal valuation exemption in section 4.4(a) of MI 61-101, on the basis that no securities of Canadian Arrow are listed on the Toronto Stock Exchange or other specified markets. Canadian Arrow will seek the requisite approvals of the Arrangement from its shareholders at the Special Meeting.
If the Arrangement is completed, the common shares of Canadian Arrow will be delisted from the TSX Venture Exchange.
None of the securities to be issued pursuant to the Arrangement Agreement have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
About Tartisan Resources Corp.
Tartisan Resources Corp. is a Canadian mineral exploration and development company focused on project generation of precious and base metal properties. Tartisan owns a 100% stake in the Don Pancho Zinc-Lead-Silver Project just 9 km from Trevali’s Santander Mine and owns a 100% stake in the Ichuna Copper-Silver Project contiguous to Buenaventura’s San Gabriel Property. Tartisan Resources portfolio also includes an equity stake (6 million shares and 3 million warrants @ 40 cents) in Eloro Resources Ltd. (TSX.V:ELO). Tartisan Resources Corp. common shares are listed on the Canadian Securities Exchange and is a Member of the CSE Composite Index (CSE:TTC). There are currently 73,052,443 shares outstanding (90,145,827 fully diluted).
About Canadian Arrow Mines Limited
Canadian Arrow is an experienced exploration and mine operating team that is focussed on acquiring and developing economically viable nickel sulphide deposits near existing infrastructure. Canadian Arrow operates in north-western Ontario, near the towns of Kenora and Dryden. The company’s main asset is the Kenbridge Nickel Project, a nickel-copper sulphide deposit containing over 98 million lbs of nickel in Measured & Indicated Resources. The deposit is equipped with a 620m shaft and has never been mined.
Additional information about Canadian Arrow can be found at the company’s website at www.canadianarrowmines.com or on SEDAR at www.sedar.com.
Forward Looking Information
Certain information contained in this news release constitutes forward looking information. All information other than information of historical fact is forward looking information. The use of any of the words “intend”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “would”, “believe”, “predict” and “potential” and similar expressions are intended to identify forward looking information. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward looking information. No assurance can be given that this information will prove to be correct and such forward looking information included in this news release should not be unduly relied upon.
The forward looking information provided in this news release is based upon a number of material factors and assumptions including, without limitation: (a) that the Arrangement will be completed in the timelines and on the terms currently anticipated; (b) that all necessary CSE, TSXV, court and regulatory approvals will be obtained on the timelines and in the manner currently anticipated; (c) that all necessary Shareholder approvals will be obtained; and (d) general assumptions respecting the business and operations of both Canadian Arrow and Tartisan, including that each business will continue to operate in a manner consistent with past practice and pursuant to certain industry and market conditions.
Readers are cautioned that the foregoing list of risks, uncertainties and assumptions are not exhaustive.
The forward looking information included in this news release is expressly qualified by this cautionary statement and is made as of the date of this news release. Neither Canadian Arrow nor Tartisan undertake any obligation to publicly update or revise any forward looking information except as required by applicable securities laws.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Canadian Arrow Mines Limited
Tetra Bio-Pharma $TBP.ca Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image
FEATURE: BetterU $BTRU.ca Focusing on #India, a High-Growth #Edtech Market, to Drive Large Sales with Strategic Partnerships #Adobe $ADBE

BTRU: TSX-V
CONNECTING GLOBAL EDUCATION WITH THE INDIAN MARKETPLACE
WHY BETTERU EDUCATION?
- The ONLY Global Education Marketplace Serving India
- betterU Partners With Adobe to Deliver Leading Digital Experience Programs in India
- Capitalizing On Mobile Payments Structure Others Unable To Provide
- Unique Ability To Collect From 200 Different Payment Methods in India
- As A Result, Leading Global Online Education Providers Use BetterU
- BetterU Receives 20 – 50% Of All Revenues Generated
- Indian Government Mandate To Educate 500 million by 2022
- India Expecting To Double Online Education From $20B to $40B
- Executed MOU with the Telecom Sector Skill Council to jointly support both organizations’ efforts towards the skilling of millions of professionals across India’s Telecom sector
Tetra Bio-Pharma $TBP.ca Signs Agreement with Partner Aphria $APH.ca to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

- Will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR)
- Signed a distribution agreement with its trusted partner Aphria to sell Rx Princepsâ„¢, its unique blend of dried medical cannabis used in its PPP0001 clinical trials
OTTAWA, ONTARIO- (Oct. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princepsâ„¢, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.
Rx Princepsâ„¢ will be a new option for doctors who want to prescribe medical cannabis, while ensuring that their patients will receive a consistent and high-quality product. Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada, thereby complying with the quality standards Tetra wants to bring to the medical community and its patients.
Rx Princepsâ„¢ will be a new therapeutic option not only for the 19% of adults who suffer from chronic pain in Canada, but also for the more than 200,000 patients already registered under the ACMPR program. Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now prepared to enter this lucrative market.
“Our objective is to position ourselves as the reference for the medical community in the prescription of medical cannabis, and gain our growing share of that market in the years to come. We believe that we are bringing additional value to patients, physicians and other key healthcare professionals involved in treating at-need patients. We are ready to launch our first medical product, and we couldn’t be more pleased to do it with a partner such as Aphria, which has demonstrated their commitment to our vision of offering a medical product of the highest quality. Our team is dedicated to make this part of our business a very successful one, bringing value to our investors in the process. Being able to generate revenue to support our operations is an important step for Tetra Bio-Pharma,” says Bernard Fortier, CEO of Tetra Bio-Pharma.
About Rx Princepsâ„¢:
Rx Princepsâ„¢ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princepsâ„¢ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.
Rx Princepsâ„¢ will be available across Canada, through Aphria’s customer service, for patients who have a prescription from their physicians.
About Aphria:
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information about Aphria, please contact:
Nina Godard – Edelman
416-455-6324
[email protected]
Vic Neufeld, President & CEO
1-844-427-4742
For further information about Tetra Bio-Pharma
and Rx Princeps(TM), please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]
American Creek $AMK.ca Commences Exploration Program on Dunwell #Mine Group of Properties in BC’S Golden Triangle

- Exploration program has commenced on Dunwell Mine group of properties
- Objectives of the program include locating adits and other historic workings and planning hole locations for a Phase 1 drill program




